Precise Delivery.
Advanced Therapies. Unprecedented.
Pneuma’s pharmaceutical delivery platform is designed to revolutionize treatment for both respiratory and systemic conditions. Our technology offers precise, efficient drug delivery directly to the lungs, improving therapeutic outcomes while minimizing side effects. With its adaptability to a wide range of pharmaceutical and OTC compounds, Pneuma's platform is unlocking new possibilities for innovative treatment approaches.
Key application areas include:
Common Lung Conditions – Precise, targeted delivery for conditions like asthma, COPD, and other respiratory disorders.
Versatile Drug Compatibility – Adaptable to various pharmaceutical compounds, including large-molecule biologics that are difficult to deliver through traditional methods.
Potential Treatments – Potential for a range of treatments, including vaccines, cannabinoids, and Traditional Chinese Medicines.
This technology is setting a new standard in drug delivery, making treatments more effective, accessible, and patient-friendly.
Drug delivery comparison
Therapeutic Platform for the Treatment of Lung Disorders
Pneuma’s Norway platform revolutionizes lung treatment with precise, user-friendly technology, delivering fragile biologics efficiently with low-shear, breath-actuated dosing and COPD medications with greater than 90% respirable fractions. Features like voice prompts, dose verification, and Bluetooth™ data sharing enhance ease of use and compliance.
Key Features:
Low-Shear Delivery – Protects fragile biologics.
Digital Breath Actuation – Propellant-free, precise dosing.
High Respirable Fraction – Up to 90% lung drug delivery.
Precision Droplet Control - Targeted delivery to different regions of the lungs.
Smart Compliance Tools – Voice prompts, dose verification, and Bluetooth™ tracking.
High Dose Confidence Mode – Ensures full dose delivery and physician insights.
Non-Small Cell Lung Cancer Research
Pneuma’s pharmaceutical platform is designed to transform how inhaled therapies are delivered, especially for lung diseases and systemic conditions. Our low-shear ejector technology ensures that large-molecule biologics, such as recombinant proteins and other complex drugs, are delivered without denaturation, preserving their efficacy. This technology supports deep lung penetration with precise, consistent dosing for a wide range of treatments.
A major focus is our collaboration with a leading U.S. cancer research center to develop inhaled therapies for non-small cell lung cancer (NSCLC) and precancerous conditions.. By delivering biologics directly to the lungs—such as licensed checkpoint inhibitors from Leads Biolabs, Inc.—we aim to enhance the efficacy of cancer treatment and address precancerous conditions.
Key Highlights
Oncology – Advancing targeted inhaled therapies for non-small cell lung cancer and precancerous conditions..
Low-Shear Technology – Preserves the structure of large-molecule biologics during delivery.
Direct Lung Delivery – Optimized for biologics to maximize therapeutic impact.
Proprietary Platform – Enables precise, efficient treatment tailored for respiratory and systemic conditions.
Combination Potential – Can be used as a standalone therapy treating precancerous conditions or in combination with systemic treatments for NSCLC.
This platform is unlocking new possibilities for targeted drug delivery, offering hope for improved outcomes in cancer care and other critical health conditions.
Pioneering the future of drug delivery through significant scientific advances in aerosol technology.
Pneuma’s technology is reshaping pharmaceutical delivery, offering a new paradigm for inhaled therapeutics. Our platform's ability to more effectively deliver small molecules and to deliver large-molecule biologics, including recombinant proteins and complex therapies, without denaturation represents a major step forward in the field. Studies demonstrate the platform's high lung penetration and precise dosing which contribute to enhanced therapeutic efficacy and safety. These findings highlight the potential to improve treatment outcomes for conditions like asthma, COPD, and non-small cell lung cancer.